P2Y12 receptor antagonist / Thienopyridine antiplatelet agent

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

7 marketed 2 in Phase 3

This page covers all P2Y12 receptor antagonist / Thienopyridine antiplatelet agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P2Y12 receptor, Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter.

Targets

P2Y12 receptor · Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter

Marketed (7)

Clopidogrel only · Seung-Jung Park · Cardiovascular
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots.
Clopidogrel loading · Azienda Policlinico Umberto I · Cardiovascular
Clopidogrel is a prodrug that irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor.
Clopidogrel 75 · US Department of Veterans Affairs · Cardiovascular
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots.
Clopidogrel treatment · VA Office of Research and Development · Cardiovascular
Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Clopidogrel reloading · University of Pecs · Cardiovascular
Clopidogrel reloading involves administering a higher initial dose of clopidogrel to rapidly achieve platelet inhibition in acute coronary syndromes or percutaneous coronary intervention.
Plavix · Generic (originally Sanofi/BMS) · Metabolic
Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis.
Patent clopidogrel · Hospital Central San Luis Potosi, Mexico · Cardiovascular
Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.

Phase 3 pipeline (2)

Clopidogrel (SR25990) · Sanofi · Cardiovascular
Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Clopidogrel (Iscover/Plavix) · Stiftung Institut fuer Herzinfarktforschung · Cardiovascular
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.

Patent intelligence

thienopyridine antiplatelet agent patent landscape — aggregated cliff calendar, attackable patents, originator estates